In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Andreas MetousisProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-1043-6591 Hilary A KennyDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-2396-967X Aasa ShimizuDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-2631-3182 Lisa SchweizerProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-1165-7804 Shani Ben-MosheProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-7046-5423 Agnes BileczDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-5231-2669 Rahul KrishnanDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.
Jingwen ZhangDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.
Isabel AlcazarDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0000-0002-8673-515X Lucy KelliherDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0009-0008-6943-4321 Mallika RaviDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.
Tejas SamantarayDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0009-0006-4442-2207 Sabrina RichterInstitute of Computational Biology, Computational Health Center, Helmholtz Munich, Neuherberg, Germany.
Yan LiCenter for Research Informatics, The University of Chicago, Chicago, IL, USA.
Jiying WangCenter for Research Informatics, The University of Chicago, Chicago, IL, USA.
Sophia SteigerwaldProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-7513-1131 Fabian J TheisInstitute of Computational Biology, Computational Health Center, Helmholtz Munich, Neuherberg, Germany.ORCID 0000-0002-2419-1943 Florian A RosenbergerProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0003-4604-6170 Thierry M NordmannProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0002-3702-815X S Diane YamadaDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.
Ricardo LastraDepartment of Pathology, The University of Chicago, Chicago, IL, USA.
Matthias MannProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID 0000-0003-1292-4799 Ernst LengyelDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA.ORCID 0000-0001-8624-1507 Funding
Metabolic reprogramming of the tumor microenvironment and therapy resistanceR35CA264619 · NCI · UNIVERSITY OF CHICAGO · PI Ernst Lengyel · 2021 to 2026
$5.2MNCI NIH HHS R35 CA264619
6 · The paper itselfAbstract
High-grade serous carcinoma (HGSC) is the most common ovarian cancer subtype, typically diagnosed at late stages with poor prognosis. Understanding early molecular events driving HGSC progression is crucial for timely detection and development of effective treatment strategies. We performed and integrated spatial cell-type resolved proteomics and paired transcriptomics across 25 women with precursor lesions of the fallopian tube and/or HGSC. Epithelial cell signatures revealed early activation of SUMOylation machinery, increased ATR and Wnt signaling, and enhanced MHC-I antigen presentation along the disease trajectory. The stroma exhibited extracellular matrix remodeling and interferon-mediated inflammation. Serous tubal intraepithelial carcinomas (STICs) in cancer patients contained a pro-coagulative signature and reduced APOA1/2 compared to STICs in individuals without cancer. We functionally established important roles of epithelial-derived TRIP13 and SUMOylation, and cancer-associated fibroblast-derived SULF1 and BGN in HGSC progression. These findings provide unique molecular insights into HGSC pathogenesis and identify potential new therapeutic targets for intervention.
Identifiers
PMID40909841
PMCPMC12407665
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390